Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients	Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Not yet recruiting	Phase 2	2026-04-07		NCT07514455

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Boryung Pharmaceutical Co., Ltd	32
Hanyang University Guri Hospital	7
Ju Hyun Shim	2
National Cancer Center, Korea	52
Samsung Medical Center	207
Seoul National University Bundang Hospital	114
Seoul National University Hospital	277

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	338